NeuroSense Therapeutics risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for NeuroSense Therapeutics Ltd or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also Equity Screeners to view more equity screening tools
NeuroSense
NeuroSense Therapeutics Ltd has current Risk Adjusted Performance of 0.1257.
RAP
=
(ER[a] - RFR) * STD[b])/STD[b]
RFR
=
0.1257
ER[a]
=
Expected return on investing in NeuroSense Therapeutics
NeuroSense Risk Adjusted Performance Relative To Other Indicators
NeuroSense Therapeutics Ltd is considered to be number one stock in risk adjusted performance category among its peers. It is currently under evaluation in maximum drawdown category among its peers reporting about 1,260 of Maximum Drawdown per Risk Adjusted Performance. The ratio of Maximum Drawdown to Risk Adjusted Performance for NeuroSense Therapeutics Ltd is roughly 1,260
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.